COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,902 Articles (22,568 medRxiv, 8,334 bioRxiv)

Most recent first Previous |  Page 1234: Articles 12331-12340  | Next

Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation
Van Rompay, K. K. A., Olstad, K. J., Sammak, R. L., Dutra, J., Watanabe, J. K., Usachenko, J. L., Immareddy, R., Roh, J. W., Verma, A., Shaan Lakshmanappa, Y., Schmidt, B., Di Germanio, C., Rizvi, N., Stone, M., Simmons, G., Dumont, L., Allen, A. M., Lockwood, S., Pollard, R. E., Ramiro De Assis, R., Yee, J. L., Nham, P. B., Ardeshir, A. A., Deere, J. D., Patterson, J., Jain, A., Felgner, P. L., Iyer, S. S., Hartigan-O'Connor, D. J., Busch, M. P., Reader, J. R.
10.1101/2021.09.01.458520 — Posted: 2021-09-01
Analysis of changes occurring in Codon Positions due to mutations through the cellular automata transition rules
Sengupta, A., Ghosh, S., Pal Choudhury, P.
10.1101/2021.08.30.458305 — Posted: 2021-09-01
SARS-CoV-2 Variant Tracking and Mitigation: Strategies and Results from In-Person Learning at a Midwestern University in the 2020/2021 School Year
Avendano, C., Lilienfeld, A., Rulli, L., Stephens, M., Alvarez Barrios, W., Sarro, J., Pfrender, M., Miranda, M. L.
10.1101/2021.08.26.21262704 — Posted: 2021-09-01
COVID-19 scenarios for comparing the effectiveness of age-specific vaccination regimes, exemplified for the city of Aschaffenburg (Germany)
Krebs, T., von Jouanne-Diedrich, H., Moeckel, M. J.
10.1101/2021.08.31.21262915 — Posted: 2021-09-01 Discussion: Onsite
PERCOVID: A Model to Describe COVID Percolation on a Network of Social Relationships
Mathiot, J.-F., Gerbaud, L., Breton, V. J.
10.1101/2021.08.31.21262909 — Posted: 2021-09-01
Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies
Flaxman, A. D., Issema, R., Barnabas, R. V., Ross, J. M.
10.1101/2021.08.31.21262923 — Posted: 2021-09-01
Effects of 105 biological, socioeconomic, behavioural, and environmental factors on the risk of SARS-CoV-2 infection and a severe course of Covid-19: A prospective longitudinal study
Flegr, J., Flegr, P., Priplatova, L.
10.1101/2021.08.31.21262906 — Posted: 2021-09-01
Sex-associated differences between body mass index and SARS-CoV-2 antibody titers following the BNT162b2 vaccine among 2,435 healthcare workers in Japan
Yamamoto, S., Mizoue, T., Tanaka, A., Oshiro, Y., Inamura, N., Konishi, M., Ozeki, M., Miyo, K., Sugiura, W., Sugiyama, H., Ohmagari, N.
10.1101/2021.08.30.21262862 — Posted: 2021-09-01
Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., Kishony, R.
10.1101/2021.08.29.21262798 — Posted: 2021-09-01
Enzymatic Beacons for Specific Sensing of Dilute Nucleic Acid and Potential Utility for SARS-CoV-2 Detection
Zhang, X., Kotikam, V., Rozners, E., Callahan, B. P.
10.1101/2021.08.30.458287 — Posted: 2021-08-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).